Clinical trials: Advanced Tumor, open to volunteers
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Solid Tumor, Lymphoma
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
- Trial name
- NCT05357651
- Testing
- LB1410
- Where
- China
- Volunteers
- 100 people
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
Advanced Solid Tumor
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients with Advanced Solid Tumors
- Trial name
- BT02 (NCT06404905)
- Testing
- BT02 monoclonal antibody injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Triple-negative Breast Cancer
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.
- Trial name
- NCT06471205
- Testing
- BL-B01D1, PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Peritoneal Carcinomatosis, Gastric Cancer
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients.
- Trial name
- GASPACCO (NCT04595929)
- Testing
- Staging laparoscopy, 5-Fluorouracil, Leucovorin
- Where
- Russia
- Volunteers
- 304 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Cervical Carcinoma
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
For locally advanced cervical cancer, there are two main treatment options: One is radical chemoradiotherapy (a combination of radiotherapy and chemotherapy aimed at curing the disease).
- Trial name
- NCT07088731
- Testing
- Sintilimab, Concurrent chemo-radiotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
EGFR Positive Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
Osimertinib for Advanced EGFR-positive NSCLC Patients
Lung cancer is the leading cause of cancer incidence (11.6%) and mortality (18.4%) globally[1]. Development of targeted therapies in the context of precision medicine changed the way lung cancer was diagnosed and treated.
- Trial name
- NCT05037331
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University Hospital, Singapore
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
- Trial name
- NCT06901622
- Testing
- Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Solid Tumor, Adult, Metastatic Solid Tumor
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab…
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
- Trial name
- NCT05856981
- Testing
- ADU-1805, Pembrolizumab
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 130 people
- Sponsor
- Sairopa B.V.
Advanced Solid Tumor
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors
A Phase I/IIa clinical study SGT003 in patients with advanced solid tumors.
- Trial name
- NCT07811037
- Testing
- SGT003
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT07791745
- Testing
- Enlituo® + Anyouping® + PBC
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Lung Cancer
Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment
This study will compare the effects of a brief supportive intervention, called Pathways, against enhanced usual care on the mental health and quality of life of people undergoing treatment for advanced lung cancer.
- Trial name
- NCT06047301
- Testing
- Pathways, Enhanced Usual Care
- Where
- United States
- Volunteers
- 234 people
- Sponsor
- Laurie McLouth
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
UNLOCK ASP3082 is an open label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to ASP3082 in metastatic/locally advanced Non-Samll-Cell Lung Cancer (NSCLC) and…
- Trial name
- UNLOCK ASP3082 (NCT07483983)
- Testing
- ASP3082
- Where
- 7 sites in France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pancreatic Cancer Metastatic
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
This is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients.
- Trial name
- NCT07920731
- Testing
- imotuzumab combined with the NALIRIFOX chemotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Advanced Gastric and Pancreatic Cancer
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
The goal of this clinical trial is to learn if CBG131 works to treat advanced gastric cancer or pancreatic cancer in adults whose tumors are CLDN18.2-positive.
- Trial name
- NCT07394205
- Testing
- CBG131 CAR-T Cell Infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Recurrent/Metastatic Endometrial Cancer
Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial
This study takes investigator-assessed Progression-Free Survival (PFS) as the primary endpoint, with plans to enroll 140 patients with advanced recurrent/metastatic endometrial cancer in a 1:1 ratio, randomized into an…
- Trial name
- A-CAPE (NCT06771154)
- Testing
- Adebelimab Combined with Apatinib, Adebelimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking Union Medical College Hospital
Non-Small Cell Lung Cancer
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally…
- Trial name
- WUKONG-32 (NCT06348927)
- Testing
- sunvozertinib in combination with Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Hunan Province Tumor Hospital
Stomach Cancer Stage IV, Esophagus Cancer
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
- Conditions
- Stomach Cancer Stage IV, Esophagus Cancer, Stomach Cancer
- Trial name
- NCT07070466
- Testing
- Ivonescimab, 5-Fluorouracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Advanced Non-small Cell Lung Cancer (NSCLC)
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
- Trial name
- INNOVA-LUNG (NCT07649629)
- Testing
- Plasma-based liquid biopsy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Regina Elena Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.